Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology and Medical Oncology Fellowship, Medicine, Duke University School of Medicine 2011 - 2015
  • Internal Medicine Chief Resident, Medicine, Duke University School of Medicine 2012 - 2013
  • Categorical Internal Medicine Residency, Medicine, Duke University School of Medicine 2008 - 2011
  • M.D., Indiana University, School of Medicine 2008
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2015 - 2017
  • Medical Instructor in the Department of Medicine, Medicine, General Internal Medicine, Medicine 2012 - 2013
• Research
• 

  Selected Grants

  • Race-related differential RNA splicing: novel targets for precision oncology in non-small cell lung cancer awarded by National Institutes of Health 2020 - 2025
  • Prospective collection of donor tissue and blood or leukapheresis product from patients with solid tumours to enable development of methods for the manufacturing of clonal neoantigen T cell products (cNeT). awarded by Achilles Therapeutics 2020 - 2025
  • A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety andTolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participa awarded by GlaxoSmithKline 2019 - 2024
  • Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) (PACIFIC-4/RTOG-3515) awarded by AstraZeneca Pharmaceuticals, LP 2020 - 2024
  • A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAF V600E-mutant Non-small Cell Lung Cancer awarded by Array BioPharma Inc 2019 - 2024
  • Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for Patients with Stage III Unresectable NSCLC awarded by H. Lee Moffitt Cancer Center & Research Institute 2019 - 2024
  • A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Taxane in Patients with Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial) awarded by Bristol-Myers Squibb Company 2018 - 2023
  • A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1) awarded by Spectrum Pharmaceuticals, Inc 2017 - 2022
  • CBMG NSCLC Tumor Specimens for TIL Cell Therapy awarded by Cellular Biomedicine Group, Inc. 2020 - 2022
  • Race-related differential RNA splicing: novel targets for precision oncology in non-small cell lung cancer awarded by Department of Defense 2020 - 2022
  • A Phase 1 Dose Escalation and Phase 2 Randomized, Open-Label Study of Nivolumab and Veliparib in Combination with Platinum Doublet Chemotherapy in Subjects with Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) awarded by AbbVie Inc. 2017 - 2022
  • Adaptimmune SURPASS awarded by Adaptimmune Limited 2019 - 2021
  • Cell-Free DNA for Diagnosis of Malignancy, Genetic Mutations and Prognosis in Lung Cancer Related Pleural Effusions awarded by Department of Defense 2020 - 2021
  • A phase I/IIa study of BMS986148 a Mesothelin directed antibody drug conjugate in subjects with select advanced solid tumors awarded by Bristol-Myers Squibb Company 2015 - 2021
  • AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, EMURAFENIB/COBIMETINIB, VISMODEGIB, ALECTINIB,AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDIC awarded by Genentech, Inc. 2016 - 2021
  • Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer awarded by National Institutes of Health 2014 - 2021
  • A screening protocol to determine tumor antigen expression and HLA sub-type ofr eligibility determination for clinical trials evaluating the safety and efficacy of Autologous T Cell expressing enhance awarded by Adaptimmune Limited 2016 - 2021
  • A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors awarded by Moderna Therapeutics, Inc. 2017 - 2020
  • Adaptimmune MAGE A-4 awarded by Adaptimmune Limited 2018 - 2020
  • A Phase III, Multicenter, Rancomized Open-Label Study Evaluating the Efficacy and Safety of MPD3280A (Anti-PD-L1 Antibody)in Combination with Carboplatin + NAB-Paclitaxel for Chemotherapy-Naive Patients with Stage IV NSCLC awarded by F. Hoffmann-La Roche Ltd 2015 - 2020
  • Adaptimmune MAGE awarded by Adaptimmune Limited 2018 - 2020
  • First-in-human dose escalation of TEW-7197 monotherapy in subjects with advanced stage solid tumors awarded by MedPacto, Inc 2014 - 2020
  • An open-label Phase I dose-escalation study to evaluate the safety, tolerability, max. tolerated dose, pharmacokinetics,and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects w/ advanced solid tumors known to expressC4 awarded by Bayer HealthCare AG 2017 - 2019
  • A phase Ib study of combination Regorafenib with PF-03446962 in patient with refactory metastatic colorectal cancer or GIST. awarded by Pfizer, Inc. 2013 - 2019
  • Identification of Genetic Determinates for Disparities in African American Patients with Non-Small Cell Lung Cancer awarded by V Foundation for Cancer Research 2016 - 2018
  • Evaluation of Tumor Infiltrating Lymphocytes in Resected Non Small Cell Lung Cancer awarded by Lung Cancer Initiative of North Carolina 2015 - 2018
  • A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor Administered with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours awarded by Eli Lilly and Company 2016 - 2018
  • Blood-based Biomarker Profiling for TEW-7197 awarded by MedPacto, Inc 2016 - 2018
• 

  External Relationships

  • Astra Zeneca
  • AstraZeneca
  • Eli Lilly & Co.
  • Guardant Health
  • Lung Cancer Initiative of North Carolina
  • Merck
  • NGM Biopharmaceuticals
  • Pfizer Inc.
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Jug, Rachel, Coral X. Giovacchini, Beiyu Liu, Cynthia L. Green, Jeffrey M. Clarke, Kamran Mahmood, and Elizabeth N. Pavlisko. “EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.” J Am Soc Cytopathol 9, no. 6 (November 2020): 485–93. https://doi.org/10.1016/j.jasc.2020.04.003.
       Full Text  Link to Item
    • Negrao, Marcelo V., Victoria M. Raymond, Richard B. Lanman, Jacqulyne P. Robichaux, Junqin He, Monique B. Nilsson, Patrick K. S. Ng, et al. “Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.” J Thorac Oncol 15, no. 10 (October 2020): 1611–23. https://doi.org/10.1016/j.jtho.2020.05.021.
       Full Text  Link to Item
    • Tang, Dongfang, Yu C. Zhao, Hongliang Liu, Sheng Luo, Jeffrey M. Clarke, Carolyn Glass, Li Su, et al. “Potentially functional genetic variants in PLIN2, SULT2A1 and UGT1A9 genes of the ketone pathway and survival of nonsmall cell lung cancer.” Int J Cancer 147, no. 6 (September 15, 2020): 1559–70. https://doi.org/10.1002/ijc.32932.
       Full Text  Open Access Copy  Link to Item
    • Deng, Wei, Hongliang Liu, Sheng Luo, Jeffrey Clarke, Carolyn Glass, Li Su, Lijuan Lin, David C. Christiani, and Qingyi Wei. “APOB Genotypes and CDH13 Haplotypes in the Cholesterol-Related Pathway Genes Predict Non-Small Cell Lung Cancer Survival.” Cancer Epidemiol Biomarkers Prev 29, no. 6 (June 2020): 1204–13. https://doi.org/10.1158/1055-9965.EPI-19-1262.
       Full Text  Open Access Copy  Link to Item
    • Jung, Su Young, Sunjin Hwang, Jeffery M. Clarke, Todd M. Bauer, Vicki L. Keedy, Hukeun Lee, Neunggyu Park, Seong-Jin Kim, and Jangik I. Lee. “Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study.” Invest New Drugs 38, no. 3 (June 2020): 812–20. https://doi.org/10.1007/s10637-019-00835-y.
       Full Text  Link to Item
    • Jacobs, Corbin D., Junheng Gao, Xiaofei Wang, Jeffrey M. Clarke, Betty Tong, Neal E. Ready, Gita Suneja, Chris R. Kelsey, and Jordan A. Torok. “Definitive Radiotherapy for Inoperable Stage IIB Non-small-cell Lung Cancer: Patterns of Care and Comparative Effectiveness.” Clin Lung Cancer 21, no. 3 (May 2020): 238–46. https://doi.org/10.1016/j.cllc.2019.10.005.
       Full Text  Link to Item
    • Moravan, Michael J., Peter E. Fecci, Carey K. Anders, Jeffrey M. Clarke, April K. S. Salama, Justus D. Adamson, Scott R. Floyd, et al. “Current multidisciplinary management of brain metastases.” Cancer 126, no. 7 (April 1, 2020): 1390–1406. https://doi.org/10.1002/cncr.32714.
       Full Text  Link to Item
    • Jung, Su Young, Ji Seob Yug, Jeffery M. Clarke, Todd M. Bauer, Vicki L. Keedy, Sunjin Hwang, Seong-Jin Kim, Eun Kyoung Chung, and Jangik I. Lee. “Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors.” Cancer Chemother Pharmacol 85, no. 1 (January 2020): 173–83. https://doi.org/10.1007/s00280-019-03979-z.
       Full Text  Link to Item
    • Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).” Cancer Chemother Pharmacol 84, no. 4 (October 2019): 909–17. https://doi.org/10.1007/s00280-019-03916-0.
       Full Text  Link to Item
    • Marano, A. L., J. M. Clarke, M. A. Morse, A. Shah, W. Barrow, M. A. Selim, R. P. Hall, and A. R. Cardones. “Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.” Br J Dermatol 181, no. 3 (September 2019): 580–83. https://doi.org/10.1111/bjd.17245.
       Full Text  Link to Item
    • Tan, Irena, Thomas E. Stinchcombe, Neal E. Ready, Jeffrey Crawford, Michael B. Datto, Rebecca J. Nagy, Richard B. Lanman, Lin Gu, and Jeffrey M. Clarke. “Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study.” Transl Lung Cancer Res 8, no. 3 (June 2019): 258–67. https://doi.org/10.21037/tlcr.2019.04.03.
       Full Text  Link to Item
    • DeMaio, Andrew, Jeffrey M. Clarke, Rajesh Dash, Siby Sebastian, Momen M. Wahidi, Scott L. Shofer, George Z. Cheng, Xuechan Li, Xiaofei Wang, and Kamran Mahmood. “Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.” J Bronchology Interv Pulmonol 26, no. 2 (April 2019): 96–101. https://doi.org/10.1097/LBR.0000000000000534.
       Full Text  Link to Item
    • Pabla, Sarabjot, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jacob Hagen, et al. “Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.” J Immunother Cancer 7, no. 1 (February 1, 2019): 27. https://doi.org/10.1186/s40425-019-0506-3.
       Full Text  Link to Item
    • Shariff, Afreen Idris, Sohail Syed, Rebecca A. Shelby, Jeremy Force, Jeffrey Melson Clarke, David D’Alessio, and Leonor Corsino. “Novel cancer therapies and their association with diabetes.” J Mol Endocrinol 62, no. 2 (February 1, 2019): R187–99. https://doi.org/10.1530/JME-18-0002.
       Full Text  Link to Item
    • Conroy, Jeffrey M., Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, et al. “Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.” J Immunother Cancer 7, no. 1 (January 24, 2019): 18. https://doi.org/10.1186/s40425-018-0489-5.
       Full Text  Link to Item
    • Velikova, Galina, Linda Jane Williams, Sarah Willis, J Michael Dixon, Juliette Loncaster, Matthew Hatton, Jacqueline Clarke, Ian H. Kunkler, Nicola S. Russell, and Nicola S. MRC SUPREMO trial UK investigators. “Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.” Lancet Oncol 19, no. 11 (November 2018): 1516–29. https://doi.org/10.1016/S1470-2045(18)30515-1.
       Full Text  Link to Item
    • Clarke, Jeffrey M., Daniel J. George, Stacey Lisi, and April K. S. Salama. “Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.” Target Oncol 13, no. 1 (February 2018): 1–20. https://doi.org/10.1007/s11523-017-0549-7.
       Full Text  Link to Item
    • Jacobs, M. T., N. A. Mohindra, L. Shantzer, I. L. Chen, H. Phull, W. Mitchell, V. M. Raymond, et al. “Use of low-frequency driver mutations detected by cell-free circulating tumor DNA to guide targeted therapy in non-small-cell lung cancer: A multicenter case series.” Jco Precision Oncology 2 (January 1, 2018). https://doi.org/10.1200/PO.17.00318.
       Full Text
    • Yi, John S., Neal Ready, Patrick Healy, Chelsae Dumbauld, Robyn Osborne, Mark Berry, Debra Shoemaker, et al. “Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.” Clin Cancer Res 23, no. 24 (December 15, 2017): 7474–82. https://doi.org/10.1158/1078-0432.CCR-17-2005.
       Full Text  Link to Item
    • Nayar, Gautam, Tiffany Ejikeme, Pakawat Chongsathidkiet, Aladine A. Elsamadicy, Kimberly L. Blackwell, Jeffrey M. Clarke, Shivanand P. Lad, and Peter E. Fecci. “Leptomeningeal disease: current diagnostic and therapeutic strategies.” Oncotarget 8, no. 42 (September 22, 2017): 73312–28. https://doi.org/10.18632/oncotarget.20272.
       Full Text  Link to Item
    • Bedoya, Armando, Kristen Glisinski, Jeffrey Clarke, Richard N. Lind, Charles Edward Buckley, and Scott Shofer. “Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases.” Am J Case Rep 18 (July 31, 2017): 842–46. https://doi.org/10.12659/ajcr.904416.
       Full Text  Link to Item
    • Clarke, Jeffrey M., Xiaofei Wang, and Neal E. Ready. “Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?” Transl Lung Cancer Res 4, no. 6 (December 2015): 804–8. https://doi.org/10.3978/j.issn.2218-6751.2015.05.03.
       Full Text  Link to Item
    • Hatch, Ace J., Jeffrey M. Clarke, Andrew B. Nixon, and Herbert I. Hurwitz. “Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.” Cancer J 21, no. 4 (July 2015): 322–26. https://doi.org/10.1097/PPO.0000000000000129.
       Full Text  Link to Item
    • Lyman, Gary H., Kari Bohlke, Alok A. Khorana, Nicole M. Kuderer, Agnes Y. Lee, Juan Ignacio Arcelus, Edward P. Balaban, et al. “Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.” J Clin Oncol 33, no. 6 (February 20, 2015): 654–56. https://doi.org/10.1200/JCO.2014.59.7351.
       Full Text  Link to Item
    • Clarke, J. M., H. I. Hurwitz, and F. Rangwala. “Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.” Cancer Treat Rev 40, no. 9 (October 2014): 1065–72. https://doi.org/10.1016/j.ctrv.2014.07.001.
       Full Text  Link to Item
    • Clarke, Jeffrey M., and Herbert I. Hurwitz. “Understanding and targeting resistance to anti-angiogenic therapies.” J Gastrointest Oncol 4, no. 3 (September 2013): 253–63. https://doi.org/10.3978/j.issn.2078-6891.2013.036.
       Full Text  Link to Item
    • Clarke, Jeffrey Melson, and Herbert I. Hurwitz. “Targeted inhibition of VEGF receptor 2: an update on ramucirumab.” Expert Opin Biol Ther 13, no. 8 (August 2013): 1187–96. https://doi.org/10.1517/14712598.2013.810717.
       Full Text  Link to Item
    • Lyman, Gary H., Alok A. Khorana, Nicole M. Kuderer, Agnes Y. Lee, Juan Ignacio Arcelus, Edward P. Balaban, Jeffrey M. Clarke, et al. “Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.” J Clin Oncol 31, no. 17 (June 10, 2013): 2189–2204. https://doi.org/10.1200/JCO.2013.49.1118.
       Full Text  Link to Item
    • Clarke, J. M., and A. J. Armstrong. “Novel therapies for the treatment of advanced prostate cancer.” Curr Treat Options Oncol 14, no. 1 (March 2013): 109–26. https://doi.org/10.1007/s11864-012-0222-4.
       Full Text  Link to Item
    • Clarke, Jeffrey M., and Herbert I. Hurwitz. “Ziv-aflibercept: binding to more than VEGF-A--does more matter?” Nat Rev Clin Oncol 10, no. 1 (January 2013): 10–11. https://doi.org/10.1038/nrclinonc.2012.197.
       Full Text  Link to Item
    • Mis, L., and J. M. Clarke. “Ipilimumab-induced pneumonitis: A case report.” Journal of Pharmacy Technology 29, no. 2 (January 1, 2013): 94–98. https://doi.org/10.1177/875512251302900207.
       Full Text
    • Clarke, Jeffrey M., and Paul Helft. “Long-term survival of a woman with well differentiated papillary mesothelioma of the peritoneum: a case report and review of the literature.” J Med Case Rep 4 (October 29, 2010): 346. https://doi.org/10.1186/1752-1947-4-346.
       Full Text  Link to Item
    • Clarke, Jeffrey M., Michael A. Morse, H Kim Lyerly, Timothy Clay, and Tayuka Osada. “Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.” Expert Opin Biol Ther 10, no. 6 (June 2010): 875–83. https://doi.org/10.1517/14712591003798278.
       Full Text  Link to Item
    • Struck, A., T. Howard, E. G. Chiorean, J. M. Clarke, R. Riffenburgh, and H. R. Cardenes. “Non-ampullary duodenal adenocarcinoma: Factors important for relapse and survival (Journal of Surgical Oncology (2009) 100, 2, (144-148)).” Journal of Surgical Oncology 100, no. 5 (October 1, 2009): 434. https://doi.org/10.1002/jso.21396.
       Full Text
    • Struck, Aaron, Thomas Howard, Elena G. Chiorean, Jeffrey M. Clarke, Robert Riffenburgh, and Higinia R. Cardenes. “Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival.” J Surg Oncol 100, no. 2 (August 1, 2009): 144–48. https://doi.org/10.1002/jso.21319.
       Full Text  Link to Item

  • Conference Papers

    • Lee, J. I., S. Y. Jung, J. S. Yug, E. K. Chung, V. L. Keedy, T. M. Bauer, J. M. Clarke, et al. “POPULATION PHARMACOKINETICS OF A NOVEL TGF-BETA RECEPTOR I KINASE INHIBITOR VACTOSERTIB IN PATIENTS WITH ADVANCED-STAGE SOLID TUMORS.” In Clinical Pharmacology & Therapeutics, 105:S103–S103. WILEY, 2019.
       Link to Item
    • Tan, Irena, Tom Stinchcombe, Neal E. Ready, Michael B. Datto, Rebecca J. Nagy, Lin Gu, and Jeffrey Melson Clarke. “Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: A single institution, retrospective cohort study.” In Journal of Clinical Oncology, 36:e21222–e21222. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e21222.
       Full Text
    • Patel, Sandip Pravin, Scott Morris, Young Kwang Chae, and Jeffrey Melson Clarke. “RNA turbulence by tumor type: Overexpression of actionable mRNA signaling pathways by histology.” In Journal of Clinical Oncology, 35:e23213–e23213. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e23213.
       Full Text
    • Yi, John, Jeffrey Melson Clarke, Patrick Healy, Xiaofei F. Wang, Debra Shoemaker, Mark W. Onaitis, Chelsae Dumbauld, et al. “Immune profiling of circulating T cells and TILs following neoadjuvant ipilimumab and chemotherapy in non-small cell lung cancer (NSCLC).” In Journal of Clinical Oncology, 35:26–26. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.7_suppl.26.
       Full Text
    • Demaio, A., R. C. Dash, S. Sebastian, J. M. Clarke, M. M. Wahidi, and K. Mahmood. “Comprehensive Genetic Mutation Analysis On Pleural Effusions Related To Lung Adenocarcinoma.” In American Journal of Respiratory and Critical Care Medicine, Vol. 195. AMER THORACIC SOC, 2017.
       Link to Item
    • Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL).” In Journal of Clinical Oncology, 34:e15013–e15013. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e15013.
       Full Text
    • Clarke, Jeffrey Melson, Herbert Pang, Mark D. Starr, Ace Joseph Hatch, Hedy Lee Kindler, Eileen Mary O’Reilly, Federico Innocenti, Alan P. Venook, Herbert Hurwitz, and Andrew B. Nixon. “Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance).” In Journal of Clinical Oncology, 33:306–306. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.3_suppl.306.
       Full Text
    • Liu, Yingmiao, Jeffrey Melson Clarke, Mark D. Starr, John C. Brady, Herbert Pang, Christel Rushing, Delia Alvarez, et al. “Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial.” In Journal of Clinical Oncology, 32:11020–11020. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.11020.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.